Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: Empirical data and simulation of collimating plaques

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 10, 2004, Pages 3425-3434

  Puusaari, Ilkka ^a   Heikkonen, Jorma ^a   Kivelä, Tero ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 125;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CATARACT; COLLIMATOR; DOSIMETRY; FEMALE; FOLLOW UP; HUMAN; MALE; OPTIC NERVE; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION HAZARD; REGRESSION ANALYSIS; RETINA MACULA LUTEA; RETROSPECTIVE STUDY; SIMULATION; TUMOR VOLUME; UVEA MELANOMA; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; EYE INJURIES; FEMALE; HUMANS; IODINE RADIOISOTOPES; LENS, CRYSTALLINE; MACULA LUTEA; MALE; MELANOMA; MIDDLE AGED; OPTIC NERVE; PHANTOMS, IMAGING; PROPORTIONAL HAZARDS MODELS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; UVEAL NEOPLASMS; VISION, LOW;

EID: 4644250109     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0066     Document Type: Article

References (50)

1. Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivelä T. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology. 2003;110:2223-2234.
2. Shields CL, Naseripour M, Cater J, et al. Plaque radiotherapy for large posterior uveal melanomas (≥8-mm thick) in 354 consecutive patients. Ophthalmology. 2002;109:1838-1849.
3. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119:969-982.
4. Astrahan MA, Luxton G, Pu Q, Petrovich Z. Conformal episcleral plaque therapy. Int J Radiat Oncol Biol Phys. 1997;39:505-519.
5. Astrahan MA, Luxton G, Jozsef G, et al. An interactive treatment planning system for ophthalmic plaque radiotherapy. Int J Radiat Oncol Biol Phys. 1990;18:679-687.
6. Packer K. Verification of ophthalmic brachytherapy treatment planning. Australas Phys Eng Sci Med. 2001;24:177-180.
7. Knutsen S, Hafslund R, Monge OR, et al. Dosimetric verification of a dedicated 3D treatment planning system for episcleral plaque therapy. Int J Radiat Oncol Biol Phys. 2001;51:1159-1166.
8. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma I: characteristics of patients enrolled and not enrolled. COMS report no. 9. Am J Ophthalmol. 1998;125:767-778.
9. Heikkonen J, Summanen P, Immonen I, et al. Radiotherapy of malignant melanoma of the uvea with 1-125 seeds. Acta Ophthalmol (Copenh). 1992;70:780-785.
10. 125I seeds. Med Phys. 1985;12:652-655.
11. 125I seed eye plaques. Med Phys. 1986;13:78-83.
12. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys. 1995;22:209-234.
13. Astrahan MA. A patch source model for treatment planning of ruthenium ophthalmic applicators. Med Phys. 2003;30:1219-1228.
14. 125I ophthalmic plaque brachytherapy. Med Phys. 1990;17:1053-1057.
15. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985;58:515-528.
16. van den Aardweg GJ, Kilic E, de Klein A, Luyten GP. Dose fractionation effects in primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci. 2003;44:4660-4664.
17. Schenken LL, Hagemann RF. Time/dose relationship in experimental radiation cataractogenesis. Radiology. 1975;117:193-198.
18. Puusaari I, Heikkonen J, Kivelä T. Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology. In press.
19. Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall; 1991.
20. Caplan RJ, Pajak TF, Cox JD. Analysis of the probability and risk of cause-specific failure. Int J Radiat Oncol Biol Phys. 1994;29:1183-1186.
21. Chappell R. Re: Caplan et al. Int J Radiat Oncol Biol Phys. 1994;29:1183-1186, and Bentzen et al. Int J Radiat Oncol Biol Phys. 1995;32:1531-1534. Int J Radiat Oncol Biol Phys. 1996;36:988-989.
22. Chappell R. Re: Caplan et al. Int J Radiat Oncol Biol Phys. 1994;29:1183-1186, and Bentzen et al. Int J Radiat Oncol Biol Phys. 1995;32:1531-1534. Int J Radiat Oncol Biol Phys. 1996;36:988-989.
23. Chappell R. Re: Caplan et al. Int J Radiat Oncol Biol Phys. 1994;29:1183-1186, and Bentzen et al. Int J Radiat Oncol Biol Phys. 1995;32:1531-1534. Int J Radiat Oncol Biol Phys. 1996;36:988-989.
24. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
25. Gray RJ. A class of K-sample tests for comparing cumulative incidence of a competing risk. Ann Stat. 1998;16:1141-1154.
26. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.
27. Hair JF Jr, Tatham RL, Anderson RE, Black WC. Multivariate Data Analysis. 5th ed. Upper Saddle River, NJ: Prentice-Hall; 1998.
28. Hosmer DW Jr, Lemeshow S. Applied Survival Analysis. Regression Modeling of Time to Event Data. New York: Wiley; 1999.
29. Parmar MKB, Machin D. Survival Analysis. A Practical Approach. Chichester, UK: John Wiley & Sons; 1995.
30. Cleves M. Analysis of multiple failure-time data with Stata. Stata Technical Bulletin. College Station, TX: Stata; 1999.
31. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc. 1989;84:1074-1078.
32. Henk JM, Whitelocke RA, Warrington AP, Bessell EM. Radiation dose to the lens and cataract formation. Int J Radiat Oncol Biol Phys. 1993;25:815-820.
33. Meecham WJ, Char DH, Kroll S, Castro JR, Blakely EA. Anterior segment complications after helium ion radiation therapy for uveal melanoma: radiation cataract. Arch Ophthalmol. 1994;112:197-203.
34. Gragoudas ES, Egan KM, Walsh SM, Regan S, Munzenrider JE, Taratuta V. Lens changes after proton beam irradiation for uveal melanoma. Am J Ophthalmol. 1995;119:157-l64.
35. Brown GC, Shields JA, Sanborn G, Augsburger JJ, Savino PJ, Schatz NJ. Radiation retinopathy. Ophthalmology. 1982;89:1494-1501.
36. Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM. Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology. 1999;106:1571-1578.
37. Brown GC, Shields JA, Sanborn G, Augsburger JJ, Savino PJ, Schatz NJ. Radiation optic neuropathy. Ophthalmology. 1982;89:1489-1493.
38. Jiang GL, Tucker SL, Guttenberger R, et al. Radiation-induced injury to the visual pathway. Radiother Oncol. 1994;30:17-25.
39. Lommatzsch PK, Alberti W, Lommatzsch R, Rohrwacher F. Radiation effects on the optic nerve observed after brachytherapy of choroidal melanomas with 106Ru/106Rh plaques. Graefes Arch Clin Exp Ophthalmol. 1994;232:482-487.
40. Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW. Radiation complications and tumor control after plaque radiotherapy of choroidal melanoma with macular involvement. Am J Ophthalmol. 1999;127:579-589.
41. Nag S, Quivey J, Earle J, et al. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56:544-555.
42. Melia BM, Abramson DH, Albert DM, et al. Collaborative Ocular Melanoma Study (COMS) randomized trial of 1-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS report no. 16. Ophthalmology. 2001;108:348-366.
43. 125I plaque therapy for uveal melanoma: analysis of the impact of time and dose factors on local control. Cancer. 1996;77:2356-2362.
44. Hall EJ, Brenner DJ. The dose-rate effect in interstitial brachytherapy: a controversy resolved. Br J Radiol. 1992;65:242-247.
45. Sia S, Harper C, McAllister I, Perry A. Iodine-125 episcleral plaque therapy in uveal melanoma. Clin Exp Ophthalmol. 2000;28:409-413.
46. 125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys. 1993;26:613-618.
47. Hall EJ, Brenner DJ. The dose-rate effect revisited: radiobiological considerations of importance in radiotherapy. Int J Radiat Oncol Biol Phys. 1991;21:1403-1414.
48. Jones R, Gore E, Mieler W, et al. Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects. Int J Radiat Oncol Biol Phys. 2002;52:989-995.
49. Bechrakis NE, Bornfeld N, Zoller I, Foerster MH. Iodine 125 plaque brachytherapy versus transscleral tumor resection in the treatment of large uveal melanomas. Ophthalmology. 2002;109:1855-186l.
50. Kivelä T, Puusaari I, Damato B. Transscleral resection vs. iodine brachytherapy for choroidal malignant melanomas 6 millimeters or more in thickness: a matched case-control study. Ophthalmology. 2003;110:2235-2244.